Reuters logo
BRIEF-GSK, Genmab apply to broaden Arzerra label in Europe
October 4, 2013 / 8:09 AM / 4 years ago

BRIEF-GSK, Genmab apply to broaden Arzerra label in Europe

COPENHAGEN, Oct 4 (Reuters) - Danish biotech firm Genmab A/S and GlaxoSmithKline said on Friday: * Have applied to the Marketing Authorization to the European Medicines Agency (EMA) to broaden label for cancer drug Arzerra (ofatumumab) in combination with an alkylator-based therapy.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below